Angiology

BIOMODEX Expands Product Offerings with Innovative Transseptal Puncture Training Solution

Thursday, January 14, 2021 - 10:12pm

BOSTON, Jan. 14, 2021 /PRNewswire/ -- BIOMODEX , a pioneering digital health company that offers a unique and enhanced 3D printed solution for patient specific rehearsal and physician training, today announced the launch of the company's new Transseptal Puncture Training Solution.

Key Points: 
  • BOSTON, Jan. 14, 2021 /PRNewswire/ -- BIOMODEX , a pioneering digital health company that offers a unique and enhanced 3D printed solution for patient specific rehearsal and physician training, today announced the launch of the company's new Transseptal Puncture Training Solution.
  • Biomodex's Transseptal Training Cartridges are 3D-printed using Biomodex's INVIVOTECH and ECHOTECH technologies, which integrates multiple advanced materials.
  • Reusable cartridge (inferior and superior vena cava, right atrium, aorta and mitral annulus)
    Watch this video about the Biomodex Transseptal Puncture Training system.
  • Biomodex has successfully commercialized several products for neurovascular and structural heart applications and is fast expanding its product portfolio through the application of its core technologies.

CES 2021 Mission for the human race, Pulxion's early detection technology is here to save lives

Thursday, January 14, 2021 - 8:04am

Pulxion's first product, PulStroke, is a novel fast-screening device for carotid artery stenosis, an early indicator of stroke.

Key Points: 
  • Pulxion's first product, PulStroke, is a novel fast-screening device for carotid artery stenosis, an early indicator of stroke.
  • Current clinical diagnosis procedures for early detection of carotid artery stenosis risk use Doppler ultrasound.
  • Therefore, patients without existing conditions are less willing to go through the assessment and thus lose the chance for early assessment and prevention.
  • These resources are accelerating the team's research and knowledge, and the company will be featured as a top-100 Taiwanese startup at CES 2021.

CES 2021 Mission for the Human Race, Pulxion’s Early Detection Technology Is Here to Save Lives.

Thursday, January 14, 2021 - 4:58am

Pulxions first product, PulStroke, is a novel fast-screening device for carotid artery stenosis, an early indicator of stroke.

Key Points: 
  • Pulxions first product, PulStroke, is a novel fast-screening device for carotid artery stenosis, an early indicator of stroke.
  • Current clinical diagnosis procedures for early detection of carotid artery stenosis risk use Doppler ultrasound.
  • Therefore, patients without existing conditions are less willing to go through the assessment and thus lose the chance for early assessment and prevention.
  • These resources are accelerating the teams research and knowledge, and the company will be featured as a top-100 Taiwanese startup at CES 2021.

Genuity Science Wins 2021 BIG Innovation Award for Novel Genome Sequencing Approach

Tuesday, January 12, 2021 - 7:11pm

BOSTON, Jan. 12, 2021 /PRNewswire/ -- Genuity Science , a genomics and data-sourcing, analytics and insights organization, today announced that it has been named a winner in the 2021 BIG Innovation Awards presented by the Business Intelligence Group.

Key Points: 
  • BOSTON, Jan. 12, 2021 /PRNewswire/ -- Genuity Science , a genomics and data-sourcing, analytics and insights organization, today announced that it has been named a winner in the 2021 BIG Innovation Awards presented by the Business Intelligence Group.
  • The BIG innovation Awards recognize those organizations and people who bring new ideas to life, and change the way we experience the world.
  • Genuity Science's AI technology sifted through a large amount of high-dimensional data without a starting hypothesis, allowing the teams to uncover novel causal connections at the single-cell level.
  • "We are honored to be recognized for our deep learning approach that helped, in part, discover the underlying cause of thoracic aortic aneurysms," said Tom Chittenden, PhD, DPhil, PStat, Chief Data Science Officer, Genuity Science.

Endospan Enrolls First Patient in the TRIOMPHE IDE Study

Tuesday, January 12, 2021 - 2:00pm

Endospan , a pioneer in off-the-shelf endovascular repair of aortic arch disease, announces the first implant of the NEXUS Aortic Arch Stent Graft System on a patient with a thoracic aortic aneurysm as part of the TRIOMPHE Study in Norfolk, Virginia, January 11, 2021.

Key Points: 
  • Endospan , a pioneer in off-the-shelf endovascular repair of aortic arch disease, announces the first implant of the NEXUS Aortic Arch Stent Graft System on a patient with a thoracic aortic aneurysm as part of the TRIOMPHE Study in Norfolk, Virginia, January 11, 2021.
  • The TRIOMPHE Study is a multi-arm, multi-center, non-randomized, prospective, clinical study to evaluate the safety and effectiveness of NEXUS in treating thoracic aortic lesions involving the aortic arch.
  • With the first patient enrolled in the TRIOMPHE IDE study, Endospan marks the next crucial milestone towards US approval for the NEXUS Aortic Arch Repair Stent Graft System, said Kevin Mayberry, CEO.
  • The NEXUS is specifically engineered for total endovascular arch repair to address the specific challenges of the aortic arch anatomy.

GBT Continues Research on AI Detection System

Thursday, January 7, 2021 - 11:00am

SAN DIEGO, Jan. 07, 2021 (GLOBE NEWSWIRE) -- GBT Technologies Inc. (OTC PINK:GTCH) ("GBT, or the Company), announced that its joint venture, GBT Tokenize Corp. (GBT/Tokenize), is continuing with its research associated with an AI system to detect and open clogs within arteries based on its proprietaryradio technology,which has an internal code name of Hermes.

Key Points: 
  • SAN DIEGO, Jan. 07, 2021 (GLOBE NEWSWIRE) -- GBT Technologies Inc. (OTC PINK:GTCH) ("GBT, or the Company), announced that its joint venture, GBT Tokenize Corp. (GBT/Tokenize), is continuing with its research associated with an AI system to detect and open clogs within arteries based on its proprietaryradio technology,which has an internal code name of Hermes.
  • The research is evaluating a system targeted for arterial clogs cleaning, such as a coronary artery, peripheral artery, or any other body vascular organ.
  • The research is evaluating whether the unit can use AI based and radio frequency imaging system to "see" within arteries.
  • GBT envisions this system as a creation of a global mesh network using advanced nodes and super performing new generation IC technology.

OXURION to Participate in Upcoming Investor Meetings

Thursday, January 7, 2021 - 7:00am

THR-149 has shown positive topline Phase 1 results for the treatment of DME.

Key Points: 
  • THR-149 has shown positive topline Phase 1 results for the treatment of DME.
  • The Company is currently conducting a Phase 2 clinical trial evaluating multiple injections of THR-149 with DME-patients who previously responded sub-optimally to anti-VEGF therapy.
  • Oxurion is headquartered in Leuven, Belgium, and is listed on the Euronext Brussels exchange under the symbol OXUR.
  • This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction.

Study of patients undergoing abdominal aortic aneurysm repair suggests screening guidelines may be inadequate

Tuesday, January 5, 2021 - 2:15pm

Rosemont, Ill., Jan. 05, 2021 (GLOBE NEWSWIRE) -- A retrospective study analyzing approximately 55,000 patients undergoing abdominal aortic aneurysm (AAA) repair suggests current AAA screening guidelines may be inadequate in detecting a significant number of new cases.

Key Points: 
  • Rosemont, Ill., Jan. 05, 2021 (GLOBE NEWSWIRE) -- A retrospective study analyzing approximately 55,000 patients undergoing abdominal aortic aneurysm (AAA) repair suggests current AAA screening guidelines may be inadequate in detecting a significant number of new cases.
  • The study patients were enrolled in the Vascular Quality Initiative between years 2003 and 2019.
  • Screening guidelines derived from the 2005 U.S. Preventive Services Task Force (USPTF) recommendations involve a one-time abdominal ultrasound examination only for men aged 65-75 with a history of smoking.
  • Our study additionally describes the clinical characteristics and outcomes in patients undergoing EVAR and open surgery who did not meet the currently accepted screening guidelines.

Global Choroidal Neovascularization Market (2020 to 2025) - Industry Trends, Share, Size, Growth, Opportunity and Forecast - ResearchAndMarkets.com

Wednesday, December 9, 2020 - 11:31am

The "Choroidal Neovascularization Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Choroidal Neovascularization Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025" report has been added to ResearchAndMarkets.com's offering.
  • The global choroidal neovascularization market grew at a CAGR of around 8% during 2014-2019.
  • Looking forward, the publisher expects the global choroidal neovascularization market to exhibit moderate growth during the next five years.
  • Choroidal neovascularization (CNV) refers to the creation of new blood vessels in the choroid layer of the eyes affecting the Bruch's membrane and retinal pigment epithelium (RPE).

Three Posters on SEL24/MEN1703 including Pharmacodynamic Data from the Dose Escalation Part of DIAMOND-01 Trial to be published at American Society of Hematology (ASH) Annual Meeting

Tuesday, December 1, 2020 - 12:10pm

Together with Menarini, we are fully focused on delivering the most effective and safe treatment options to cancer patients worldwide."

Key Points: 
  • Together with Menarini, we are fully focused on delivering the most effective and safe treatment options to cancer patients worldwide."
  • DIAMOND-01 is the First-in-Human, Phase I/II dose escalation and cohort expansion trial of SEL24/MEN1703, in-licensed from Ryvu Therapeutics by Menarini, in AML.
  • Hence, targeting PIM kinases may represent an efficient approach to induce tumor cell death and to block angiogenesis in MM.
  • Ryvu Therapeutics is listed on the main market of the Warsaw Stock Exchange, and has been a component of sWIG80 index since March 2017.